HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease.

Abstract
A literature search was conducted to examine the safety and effectiveness of low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Nine published articles indicated that for patients with Crohn's disease, oral or intramuscular methotrexate 20-25 mg/week is safe and effective to induce remission, followed by a lower dosage to maintain remission. In addition, methotrexate allows for corticosteroid dosage reduction. Therapy may be continued until the disease flares or adverse events occur. Evidence is insufficient to support methotrexate as treatment for ulcerative colitis.
AuthorsAlexander G Vandell, Joseph T DiPiro
JournalPharmacotherapy (Pharmacotherapy) Vol. 22 Issue 5 Pg. 613-20 (May 2002) ISSN: 0277-0008 [Print] United States
PMID12013360 (Publication Type: Journal Article, Review)
Chemical References
  • Immunosuppressive Agents
  • Methotrexate
Topics
  • Colitis, Ulcerative (drug therapy)
  • Crohn Disease (drug therapy)
  • Humans
  • Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
  • Inflammatory Bowel Diseases (drug therapy)
  • Methotrexate (administration & dosage, adverse effects, therapeutic use)
  • Secondary Prevention

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: